Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein

Anti-Cancer Drugs

Volumn 18, Issue 9, 2007, Pages 1075-1080

  Huang, Libin ^a   Wang, Chunhui ^a   Zheng, Wenbin ^a   Liu, Rui ^a   Yang, Jinlin ^a   Tang, Chengwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Celecoxib; Gastric carcinoma; Multidrug resistance; P glycoprotein

Indexed keywords

CELECOXIB; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; THYMIDINE; TRITIUM; VINCRISTINE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PYRAZOLES; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 34548107571     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3281c49d7a     Document Type: Article

References (28)

1. Schwarz RE, Zagala NK. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9:394-400.
2. Sanchez-Bueno F, Garcia-Marcilla JA, Perez-Flores D, Perez-Abad JM, Vicente R, Aranda F, et al. Prognostic factors in a series of 297 patients with gastric adenocarcinoma undergoing surgical resection. Br J Surg 1998; 85:255-260.
3. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, et al. Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002; 86:1578-1585.
4. Wilkoff W, Dulmadge EA. Resistant and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D. J Natl Cancer Inst 1978; 61:1521-1524.
5. Wong BC, Jiang X, Fan XM, Lin MC, Jiang SH, Lam SK, et al. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003; 22:1189-1197.
6. Liu C, Tang C, Wan X, Wang C, Zhou X. The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:480-483.
7. Tang C, Liu C, Zhou X, Wang C. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004; 112:470-474.
8. Zheng WB, Wang CH, Qiang O, Tang CW. Inhibitory effects of celecobix combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR. Chin J Cancer 2004; 23:1628-1632.
9. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer 2002; 95:1795-1801.
10. Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 2003; 42:237-243.
11. Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000; 267:277-294.
12. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer 2002; 95:1795-1801.
13. Petriz J, Garcia LJ. Flow cytometric analysis of P-glycoprotein function using rhodamine123. Leukemia 1997; 11:1124-1130.
14. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005; 17:86-95.
15. Cai XJ, Zhang XY, Fan DM. In vitro study of anti-cancer agents resistant patterns of resistant human gastric cancer cell lines. J Fourth Milit Med Univ 1994; 15:86-88.
16. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107:323-329.
17. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6:519-525.
18. Koga T, Shibahara K, Kabashima A, Sumiyoshi Y, Kimura Y, Takahashi I, et al. Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer. Hepatogastroenterology 2004; 51:1626-1630.
19. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue OP, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 2005; 35:707-713.
20. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53:195-200.
21. Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002; 35:843-852.
22. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002; 277:38915-38920.
23. Sonneveld P, Wiemer E. Inhibitors of mutidrug resistance. Curr Opin Oncol 1997; 9:543-548.
24. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59:957-980.
25. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40:1347-1365.
26. 2-terminal kinase. Gastroenterology 2004; 126:136-147.
27. Honjo S, Osaki M, Ardyanto TD, Hiramatsu T, Maeta N, Ito H. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 2005; 24:141-147.
28. Fan XM, Jiang XH, Gu Q, Ching YP, He H, Xia HH, et al. Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells. Digestion 2006; 73:75-83.